Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic




Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic

New funding brings total capital raised to $135 million 

Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their source

Financing will support clinical development of differentiated small molecule therapies targeting high-value inflammatory and neurological disease proteins

BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, today announced the close of a $65 million oversubscribed Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company (“Lilly”), as well as existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV and ARCH Venture Partners.

The funding will advance Gate’s lead molecular gate programs into the clinic and support the continued expansion of its differentiated molecular gate programs across inflammation and other therapeutic areas.

In connection with the financing, Vanessa Carle, Ph.D., Principal at Forbion, will join Gate’s Board of Directors, contributing extensive experience in building and scaling innovative therapeutics companies across Europe and the United States.

“Gate represents a rare opportunity to invest in a truly differentiated therapeutic modality with significant advantages over existing treatments,” said Dr. Carle. “The Company’s molecular gate platform addresses high-value, clinically validated targets across multiple therapeutic areas with an oral small molecule approach, which is something that has eluded the field until now. With its experienced team and differentiated platform, Gate is uniquely positioned to disrupt treatment paradigms in inflammatory and neurological diseases, potentially unlocking significant value across underserved markets.”

Gate’s portfolio of molecular gates targets high value, well-validated proteins in inflammatory and neurological diseases, offering the convenience of a pill and the potential for superior efficacy through a novel mechanism of action. By eliminating inflammatory proteins like cytokines inside the cell before secretion, Gate’s approach may be more effective than treatments that act only after these proteins enter circulation. In the brain, molecular gates that easily cross the blood-brain barrier can address disease-causing proteins that traditional biologics cannot.

“Molecular gates have the potential to be transformative drugs for diseases where current treatments fall short,” said Jordi Mata-Fink, Ph.D., Co-Founder and CEO of Gate Bioscience. “Because the mechanism is so differentiated, we’ve been able to build a portfolio with low biology risk and best-in-class potential across multiple therapeutic areas. We’re also seeing the fruits of our platform investment, which has matured into a true drug discovery engine that allows us to make selective molecular gates repeatedly and efficiently, both for our own pipeline and for our biopharma partners. We are grateful for the support of Forbion, Lilly, and our existing investors, which will help us test the first molecular gate medicines in the clinic and continue to expand our portfolio.”

The proceeds from the Series B will advance Gate’s lead programs through IND-enabling studies and Phase 1 clinical trials to generate clinical proof-of-concept data. Additionally, the funding will support the discovery of molecular gates to target additional high value proteins and strengthen Gate’s discovery platform to enhance speed and efficiency.

About Molecular Gates

Molecular gates are orally available small molecule drugs that eliminate a target protein potently and selectively by blocking the protein’s progress through the secretory channel Sec61, leading to its degradation. Among the approximately 4,000 targets of molecular gates are many high-value targets in the areas of immunology, neuroscience, and other diseases, which currently have no therapies or require injectables to eliminate the target protein.

About Gate Bioscience

Gate Bioscience is a biotechnology company developing molecular gates, a new class of small molecule medicines that eliminate disease-causing proteins at their source. Gate’s proprietary Molecular Gate Discovery Platform enables the rapid and repeatable discovery of selective molecular gates against high-value targets across inflammatory and neurological diseases. The platform integrates a privileged library of molecular gate compounds, a suite of secretion-focused assays and technologies, and deep expertise in the biology of the secretory pathway. For more information, visit www.gatebio.com.

About Forbion

Forbion is a leading global venture capital firm with deep roots in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm’s team of over 30 investment professionals has a strong track record, with more than 130 investments across 11 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.

Media Contact:
Carly Scaduto
THRUST Strategic Communications
carly@thrustsc.com 

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference




CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:00 a.m. GMT.

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY^® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial




MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)

Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Product Portfolio

Trial Enrollment Ongoing

MARIETTA, Ga., Nov. 13, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to evaluate the performance of the Company’s EPIEFFECT^® product in comparison to standard of care (“SOC”) wound treatment.

The study, entitled “Evaluation of lyophilized human amnion/chorion membrane (“LHACM”) in the management of nonhealing diabetic foot ulcers: an interim analysis of the CAMPAIGN trial,” was recently published in the International Journal of Tissue Repair. Enrollment for CAMPAIGN is still ongoing; however, advanced predictive models indicate superiority of MIMEDX’s EPIEFFECT over SOC based upon 71 enrolled patients. The Company also presented at the Tissue Research Evidence Summit (“TRES”) in New Orleans, La. on October 30, 2025 with an expanded 88 patient sample set, further widening the gap between EPIEFFECT and SOC.

In the CAMPAIGN study design, success was defined as a posterior probability > 90%, and the interim results demonstrated the posterior probability that LHACM was superior to standard of care was 98.5%.

“Since its launch in 2023, EPIEFFECT has garnered significant praise for its clinical efficacy and utility. Until now, this has been based solely upon real-world evidence. We are, therefore, extremely pleased with the favorable results being demonstrated in this latest RCT. Thus far, EPIEFFECT recipients outperformed those treated with SOC, and we are optimistic that this study will have a successful read out upon completion,” stated Joseph H. Capper, MIMEDX Chief Executive Officer.

“MIMEDX’s ongoing commitment to demonstrating the scientific and clinical efficacy of our product portfolio once again shines through in this interim analysis. We believe the results present a compelling case for Medicare and commercial insurance coverage for this product, particularly in light of pending Local Coverage Determination (“LCD”) implementations, scheduled for January 1, 2026. To that end, we believe our EPIEFFECT study results presented at TRES stood out as having met the current criteria for inclusion under the LCDs,” concluded Mr. Capper.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.




Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.

KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is pleased to announce that its wholly owned Florida subsidiary, Doseology USA Inc., has executed a confidential manufacturing agreement with a leading North American production partner.

This milestone represents a step in Doseology’s operational evolution—establishing the commercial infrastructure, manufacturing capacity, and regulatory foundation required to support the Company’s transition from development of its oral stimulant pouches to full market readiness.

“This is much more than a manufacturing agreement, it’s a defining moment as it enables Doseology to move from R&D to commercial deployment,” said Tim Corkum, President & COO of Doseology. “Through Doseology USA Inc., we’ve secured an American partner that delivers the scale, quality, and integrity we require as we prepare to enter the oral stimulant pouch market.”

Extensive Diligence Across North America

Doseology’s leadership conducted on-site reviews, operational assessments, and compliance audits across numerous facilities throughout the United States and Canada.

After rigorous evaluation, the Company selected a partner recognized for:

• Certified & Compliant Production: FDA-registered, GMP-certified, and ISO 9001:2015-approved facility ensuring pharmaceutical-grade quality and safety.
• Turnkey Manufacturing Expertise: End-to-end solutions spanning formulation, ingredient sourcing, blending, pouch filling, packaging, and logistics.
• Oral Pouch Specialization: Precision control across nicotine, caffeine, and nootropic pouch formats—customizable by dosage, moisture, and flavour.
• Rigorous Quality & Regulatory Systems: Built-in QA, traceability, and labeling practices fully aligned with FDA and ISO standards.
• Scalable, Low-Risk Partnership Model: Flexible production volumes that accommodate early pilot runs, regional launches, and high-volume commercial production designed to minimize capital investment while accelerating go-to-market.

“Our diligence process was deliberate and comprehensive,” added Corkum. “We wanted an American manufacturing partnership that reflects our core values—integrity, quality, and accountability. As we enter the market, this ensures Doseology’s products are built on a foundation of trusted North American craftsmanship and scientific precision.”

A Defining Milestone for Shareholders

The signing of this manufacturing agreement by Doseology USA Inc. marks a key inflection point in Doseology’s investment and commercialization cycle, demonstrating that the Company has now established the operational backbone to execute its strategy and deliver measurable progress in the oral stimulant pouch market.

“This step validates our readiness to scale,” said Corkum. “We’ve secured the right partner, the right structure, and the right systems to move confidently into the next stage of our growth. For shareholders, this milestone signals tangible execution and a disciplined pathway toward value creation.”

“This agreement represents a pivotal step in Doseology’s ability to commercialize efficiently and responsibly,” added Patrick Sills, Strategic Commercialization Advisor to Doseology. “Having worked closely with global category leaders such as Swedish Match, the parent company behind ZYN, I’ve seen firsthand how disciplined manufacturing, compliance, and scalability form the bedrock of long-term success. Doseology’s approach—combining science-driven product development with thoroughly vetted North American infrastructure—built on the same strategic foundation that defined today’s market leading oral stimulant brands. This partnership validates the Company’s commitment to execution, quality, and shareholder value.”

Building for Market Leadership

Led by executives with deep experience in regulated Big Tobacco, CPG, Nutraceuticals, and Corporate Finance, Doseology continues to build a North American infrastructure network designed to support innovation, compliance, and performance at scale.

The establishment of Doseology USA Inc. further strengthens the Company’s operational presence in the United States and underscores its commitment to American-made production integrity, sustainable growth, and long-term shareholder value.

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology is a biotech innovation company, engineering precision‑formulated oral stimulants that are designed to optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we’re pioneering next‑gen performance solutions designed to empower peak performance.

Website: www.doseology.com

Forward Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

Media Contact

Chris Jackson
Email: hello@doseology.com
Phone: 604.908.3095

IMU Biosciences announces formation of Scientific Advisory Board




IMU Biosciences announces formation of Scientific Advisory Board

PRESS RELEASE

            Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and genetics

London, UK, 13 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the formation of its Scientific Advisory Board (SAB).

Professor Paresh Vyas, Professor Bali Pulendran, Professor Adrian Hayday and Dr Peter Goodfellow, four leading academic experts in haematology, vaccinology, immunology and genetics, join the SAB as inaugural members. Their role is to provide essential guidance and input as the Company pioneers advanced immune profiling and AI analytics to decode the human immune system and its relationship to disease, to revolutionise the way immune-related diseases are understood, diagnosed and treated.

Dr Adam Laing, Co-founder and Chief Scientific Officer at IMU Biosciences, commented: “The formation of the SAB is an important step in IMU’s journey to pioneer advanced immune profiling and analysis techniques to decode the human immune system.

“We’ve assembled a team of some of the most distinguished experts whose combined experience in immunology, haematology, vaccinology, genetics and biotech innovation will prove invaluable as we continue to decode the hidden language of immunology.

“IMU’s goal is to create a paradigm shift in our ability to understand, diagnose and treat immune-related diseases, and deliver clinically actionable insights that will shape the future of precision medicine. These world-renowned experts bring significant expertise, knowledge and insights, which will be instrumental in guiding the Company as it executes its strategy.”

Professor Paresh Vyas is a distinguished academic with over 25 years of experience working at the University of Oxford where he holds multiple positions, including Professor of Haematology and Director of the Oxford Centre for Haematology. Additionally, Paresh is a Consultant Haematologist in Oxford specialising in myeloid disorders such as acute myeloid leukaemia, myelodysplastic syndrome and allogeneic stem cell transplantation. He was on the Board of NHS Blood and Transplant. He is a leading member of the UK AML Research Network, leading clinical trials in AML and MDS. He studied undergraduate medicine at the University of Oxford.

Professor Bali Pulendran is the Violetta L. Horton Professor at the Stanford University School of Medicine and the Director of Stanford’s Institute for Immunity, Transplantation and Infection. Bali’s lab pioneered the use of systems approaches to probe immunity to vaccination and infection in humans. In addition, he showed that dendritic cells comprise multiple, functionally distinct subtypes, and defined how microbial stimuli program DCs to shape T-helper responses and helped establish Flt3-Ligand as the key in-vivo growth factor for DCs. These discoveries helped define major paradigms in innate immunity. He holds a BA (Hons) in the Natural Sciences Tripos from Cambridge University and a PhD from the Walter & Eliza Hall Institute. He is fellow of the American Association for the Advancement of Science and the recipient of two concurrent MERIT awards from the NIH, the AAI Ralph Steinman Award for Human Immunology, the Albert Levy Prize, and the ViE Award for the Best Research Team at the World Vaccine Congress.

Professor Adrian Hayday is the Kay Glendinning Professor of Immunobiology at King’s College London and a Principal Group Leader at the Francis Crick Institute. Adrian’s most recognised contributions are the elucidation and characterisation of Gamma Delta T cells, including the demonstration of their tumour-targeting capacities, consequent to which he co-founded Gamma Delta Therapeutics. Additionally, over a decade of work saw his laboratory distil immune-profiling to a practical, high-content, high-resolution, high-throughput format, associated with which he was advisor to the US N.I.H. Human Immunology Project Consortium. Adrian has received numerous awards, including the William Clyde DeVane Medal, Yale’s highest honor for scholarship and teaching, and an honorary degree from Heidelberg University. He was elected to lead the British Society of Immunology, and to the Fellowships of the Royal Society and the Academy of Medical Sciences. He holds a BSc degree in Natural Sciences (biochemistry) from Cambridge University and a PhD in molecular virology from Imperial College London.

Dr Peter Goodfellow is a geneticist best known for identifying and cloning the male sex determination gene, SRY, on the human Y chromosome. Peter is currently a Scientific Advisor at Abingworth Life Sciences. Previously he was the Senior Vice President of Discovery Research at GSK. Peter has also held the Balfour Chair in Genetics at Cambridge University. He was elected a Fellow of the Royal Society in 1992 and received the Louis-Jeantet Prize for Medicine in 1995. He has been awarded BSc and DSc degrees from the University of Bristol and a DPhil from the University of Oxford. 

-ENDS-

Contacts:

About IMU Biosciences

IMU’s goal is to revolutionise the way immune-related diseases are understood, diagnosed and treated. It is pioneering advanced immune profiling and AI analytics to decode the human immune system and its relationship to disease.

Starting with a simple blood sample and building immune profiles which extend from the molecular to the population level, IMU has created the world’s largest and highest-resolution immune dataset. This novel platform applies proprietary immune analysis and machine learning to decode immune variation and its disease association at an unprecedented depth and scale.

By mapping the immune system of individuals at the molecular, cellular and system level and aggregating immune profiles from tens of thousands of people, IMU translates this into population-level insights, unlocking an unparalleled understanding of immune-driven health and disease. These clinically actionable insights are enabling IMU to uncover new immune mechanisms and deliver precision approaches for diagnosing, monitoring and treating disease, prescribing the safest and most pertinent medicines and enabling the development of next generation therapies.
  
The Company was built by a team of immune specialists and technologists based on a decade of research at King’s College London and the Francis Crick Institute.

Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris




Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company“), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH“), announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris“) will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. (CET). This trading halt takes place in the context of the previously announced public offering by the Company in the United States only of new American Depositary Shares (the “ADSs“), each representing one new ordinary share of the Company with a nominal value of €0.01 (the “Offering“), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.

This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, November 13, 2025, at approximately 3:30 p.m. (CET), which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Market (9:30 am (ET)), under the ticker symbol “IVA”.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com     

Contacts

Important Notice 

This press release contains certain forward-looking statements with respect to the proposed trading halt. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements.

Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Disclaimers

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

France

The securities offered as part of the Offering have not been and will not be offered or sold to the public in France (except for public offerings defined in Article L.411-2 1° of the French Monetary and Financial Code).

The securities offered as part of the Offering may only be offered or sold in France pursuant to Article L. 411-2 1° of the French Monetary and Financial Code to “qualified investors” (investisseurs qualifiés) (as such term is defined in Article 2(e) of Prospectus Regulation) acting for their own account, and in accordance with Articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

European Economic Area

In relation to each Member State of the European Economic Area (each, a “Member State”) no offer to the public of securities may be made in that Member State other than:

• to any legal entity which is a ‘‘qualified investor’’ as defined in the Prospectus Regulation;
• to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives of the placement agents for any such offer; or
• in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of securities shall require us or any placement agent to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the placement agents and the Company that it is a ‘‘qualified investor’’ as defined in the Prospectus Regulation.

For the purposes of this provision, the expression an “offer to the public” in relation to any securities in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any ordinary shares.

United Kingdom

This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order“), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issuance or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons“). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Attachment

• Inventiva – PR – Trading Halt – EN – 11 13 2025

Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting




Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting

• New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatment
• All six patients responded positively to the combination
• Overall response data in cohort 2 confirm EO2463 monotherapy produces marked efficacy in patients in watch-and-wait setting
• Registrational Phase 3 trial could start in 2026 in the watch-and-wait setting

Paris, France – 13 NOVEMBER 2025 (08:30 CET)

Enterome, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of memory T-cells to fight cancer, today announced positive new interim data from two cohorts of patients with low tumor-burden follicular lymphoma in the ongoing Phase 2 study of its lead OncoMimics™ immunotherapy EO2463. In cohort 3, data from the SIDNEY study showed a benign safety profile for EO2463 in combination with rituximab as first-line treatment for previously untreated patients with low tumor-burden follicular lymphoma in need of treatment, adding only injection site reactions to the well-known safety profile of rituximab. In addition, all six patients in this feasibility assessment responded to the combination treatment.

Data from cohort 2 continue to show that EO2463 monotherapy produces excellent response rates when offered to patients with newly diagnosed follicular lymphoma or marginal zone lymphoma as an alternative to standard watchful waiting, an unmet clinical need setting. Per the abstract, data from 19 evaluable patients as of July showed an overall response rate (ORR) of 47%, including 3 complete responses (CRs) and 6 partial responses (PRs). No treatment is given to patients who currently follow the standard watch and wait setting practice as long as they do not show troublesome symptoms, despite the fact that they can remain anxious about their disease, and have a decreased quality of life.

The company will present the next update on both sets of data at the 67th American Society of Hematology (ASH) meeting in Orlando, Florida, in December.

“These encouraging data further strengthen our conviction in the broad potential of EO2463 as a novel active immunotherapy. The data from the “watch-and-wait” setting confirm our earlier positive findings, while those from cohort 3 – which we had not reported on before – point in the same direction,” said Jan Fagerberg, Chief Medical Officer at Enterome.

“This is another exciting set of new data, ahead of our lead asset EO2463 entering Phase 3 testing in the “watch-and-wait” setting in 2026. The data come shortly after we received Fast Track designation for EO2463 from the U.S. FDA for the watch-and-wait setting, raising our confidence that Enterome’s OncoMimics™ platform has the potential to be applied across a broad range of cancers,” said Pierre Belichard, Chief Executive Officer of Enterome.

Details of the poster presentations:
Abstract #5377

• Title: EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/SIDNEY (NCT04669171) primary endpoint Lugano objective response analysis
• Presenting Author: Jose Caetano (JC) Villasboas, MD Mayo Clinic
• Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
• Session date: 7 December 2025
• Presentation time: 06:00-08:00 PM
• Location: Room OCCC, West Halls B3-B4

Abstract #3594

• Title: EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/SIDNEY (NCT04669171)
• Presenting Author: Stephen Smith, M.D., UW Medicine, Fred Hutchinson Cancer Research Center
• Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
• Session date: 8 December 2025
• Presentation time: 06:00-8:00 PM
• Location: Room OCCC, West Halls B3-B4

Follicular Lymphoma, one of several types of indolent Non-Hodgkin Lymphoma, is a difficult to treat chronic condition with relapses, characterized by slow progression and few symptoms, and reduced life expectancy. It is usually diagnosed by the appearance of swollen lymph nodes, and the early stages of the disease can be characterized by a lack of troublesome symptoms such as night sweats, fever or weight loss. There is a widespread consensus among leading investigators on the need for a well-tolerated and effective monotherapy to stop or slow progression for patients in the watch-and-wait setting.

EO2463 is an innovative, off-the-shelf OncoMimics™ active immunotherapy that combines four synthetic peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). It also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms such as antigen escape.

OncoMimics™ consist of bacteria-derived peptide antigens that closely mimic tumor-associated antigens (TAAs). These antigens induce a fast and potent in vivo expansion
of cytotoxic memory CD8+ T cells that were primed by gut bacteria, and are cross-reactive with TAAs. Because the peptides are “non-self”, OncoMimics™ avoid the self-tolerance that limits many cancer immunotherapies to enable rapid, potent, and durable responses to tumors. The synthetically produced peptides are designed in silico, mining Enterome’s proprietary database of 23 million commensal bacteria genes. Each product combines multiple high-affinity peptides to broaden target coverage and mitigate tumor heterogeneity.

OncoMimics™ are easy to manufacture, store, distribute and administer as an “off-the-shelf” subcutaneous injection. OncoMimics™ have achieved rapid and potent responses in clinical testing in over 230 patients to date, with a benign safety profile.

Enterome SA (www.enterome.com) is a privately held clinical-stage biopharmaceutical company developing OncoMimics™, a breakthrough in in vivo immune therapies for cancer. The three most advanced product candidates have shown positive early data in Phase 2 clinical development in more than 230 patients across solid tumors and hematological malignancies, showing correlation between clinical efficacy and induced immunogenicity and a benign safety profile, activating large quantities of endogenous memory T-cells.

For more information, please contact:

Attachment

• 20251113 – Enterome PR ASH teaser (final)

T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic




T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic

• $32 million new equity injection adds to previously announced $59 million
• New investors Tencent and BGF joined by all existing major shareholders
• Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease

13 November 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising a further $32 million. Following the initial $59 million raised, this brings the Series A total to date to $91 million.

New investors Tencent and BGF joined the Series A syndicate, alongside all existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge Venture Fund.

T-Therapeutics will use the additional proceeds to drive its pipeline of first-in-class TCR-CD3 bispecifics across oncology and autoimmune diseases towards the clinic, including the further exploration of new therapeutic strategies such as T cell subset depletion. T-Therapeutics’ lead asset in oncology exploits a pan-tumour driver target, applicable across multiple different solid tumour types. Its lead immunology programme is a pan-autoimmune bispecific designed for precision immune reset, achieved by the selective depletion of pathogenic immune cells.

Theodora Harold, Chief Executive Officer of T-Therapeutics, said: “Our transformative medicines tackle upstream disease-drivers that can have pan-indication impact. We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support.”

T-Therapeutics’ TCR platform, OpTiMus®, can generate an almost unlimited repertoire of high specificity, fully human TCRs, enabling access to validated, but previously undruggable, intracellular targets. The Company also leverages its proprietary next-generation CD3 T cell engagers (TCEs), which have been engineered for high potency, superior safety and favourable pharmacokinetics. OpTiMus-derived TCRs are combined with the proprietary TCEs to form first-in-class bispecific drug candidates. T-Therapeutics’ pipeline is focused on upstream disease-drivers with pan-indication potential to deliver significant clinical benefit for patients.

Graziano Seghezzi, Managing Partner at Sofinnova Partners, said: “The existing investors co-founded T-Therapeutics to push the boundaries of bispecific technology. This additional capital enables us to expand into T cell subset depletion, one of the most exciting areas in immunology, while continuing to advance oncology programmes. We are now ideally positioned to address both cancer and autoimmune disease, two broad disease areas with critical unmet medical needs, with a platform that unlocks targets previously considered undruggable.”

Luke Rajah, Partner at BGF, added: “This is a leadership team with an outstanding track record of building successful drug discovery businesses and translating science into medicines. Backed by a syndicate of world-class life sciences investors, T-Therapeutics is uniquely positioned to unlock previously undruggable targets with its first-in-class bispecifics. We are proud to support the team and help catalyse their programmes towards the clinic.”

Contact Us

T-Therapeutics
Theodora Harold
info@t-therapeutics.com

ICR Healthcare
Amber Fennell, David Daley, Lucy Featherstone
t-therapeutics@icrhealthcare.com

About T-Therapeutics

T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease. T-Therapeutics’ experienced team combines world-leading expertise in mouse genome engineering, single cell genomics, biopharmaceutical drug development, machine-learning and structural biology, anchored in a culture of creativity and collaboration. T-Therapeutics is developing ‘optimal’ TCR therapeutics using its proprietary OpTiMus® discovery platform, that provides an almost unlimited source of unique, antigen-specific human TCRs. The company is developing a pipeline of first-in-class drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.

The company is backed by blue-chip investors, including Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Tencent, BGF, Sanofi Ventures and, through Cambridge Enterprise, the University of Cambridge Venture Fund.

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants




Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase price of $2.599 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

The gross proceeds to Annexon from the offering are expected to be $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Annexon. The offering is expected to close on November 14, 2025, subject to the satisfaction of customary closing conditions. In addition, Annexon has granted the underwriters a 30-day option to purchase up to an additional 4,326,922 shares of common stock.

Goldman Sachs & Co. LLC, TD Cowen and Wells Fargo Securities are acting as joint book-running managers for the offering.

The shares of common stock and pre-funded warrants are being offered by Annexon pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the “SEC”) on March 26, 2024 and subsequently declared effective by the SEC on April 1, 2024. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that will form a part of the registration statement. These documents can be accessed for free through the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, by telephone at 800-645-3751 (option #5), or by email at WFScustomerservice@wellsfargo.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Annexon

Annexon, Inc. (Nasdaq: ANNX) is developing the next generation of complement inhibitors to stop neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the expected gross proceeds from the offering and the closing date of the offering. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to, among other things, market conditions and the satisfaction of customary closing conditions related to the public offering. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the preliminary prospectus supplement and the accompanying prospectus, the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:

Beth Keshishian
917-912-7195
beth@bethkeshishian.com

Caring Brands Announces Pricing of $4,000,000 Million Uplisting to Nasdaq




Caring Brands Announces Pricing of $4,000,000 Million Uplisting to Nasdaq

FORT PIERCE, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — Caring Brands, Inc. (“Caring Brands” or the “Company”), a wellness consumer products company offering several over-the-counter (OTC) and cosmetic consumer products, today announced the pricing of its underwritten U.S. public offering of 1,000,000 common shares at a public offering price of $4.00 per common share for aggregate gross proceeds of approximately US $4,000,000, prior to deducting underwriting discounts and offering expenses (the “Offering”).

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 150,000 common shares at the public offering price, less the underwriting discounts and commissions. The Offering is expected to close on November 14, 2025, subject to customary closing conditions.

In connection with the Offering, Caring Brands has received approval to list its common shares on the Nasdaq Capital Markets, with the shares expected to begin trading on or around the date of November 13, 2025 under the symbol “CABR”, at which point our common stock will cease to be traded on the OTCQB.

Caring Brands intends to use the net proceeds received from this offering for general and working capital purposes, including but not limited to marketing and sales of its proprietary products, and for the repayment of certain debt.

D. Boral Capital LLC (“D. Boral”) is acting as the sole underwriter in connection with this offering.

A registration statement on Form S-1 relating to the Offering, as amended, was filed with the Securities and Exchange Commission (the “SEC”) (File Number: 333-289767) and was automatically declared effective on October 30, 2025. The Offering is being made only by means of a prospectus. A copy of the final prospectus will be filed with the SEC, which may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022 by email to info@dboralcapital.com, or by calling (212) 970-5150.

Before you invest, you should read the registration statement, the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall there be any offer, solicitation or sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Caring Brands, Inc.

Caring Brands is a wellness consumer products company who offers several over-the-counter (OTC) and cosmetic consumer products. The Company’s product pipeline includes a diverse range of products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, and a jellyfish sting protective suncare line catering to diverse health and wellness needs. The Company’s method of operation ensures that the mechanism of action of all products is established, efficacy is determined through controlled clinical trials, products are protected by issued and filed patents, and products have acceptable commercial stability.

Forward-Looking Statement

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the proposed Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as “believe”, “plan”, “expect”, “intend”, “should”, “seek”, “estimate”, “will”, “aim” and “anticipate” or other similar expressions in the prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For further information, please contact:

Brian S John

investors@caringbrands.com

(561) 896-7616